NCT05587569 Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2022-09-28 with a primary completion date of 2026-12-31.

Brief Summary

Prospective, multicenter, unblinded study to evaluate outcomes of the Adductoplasty™ Procedure in combination with the Lapiplasty® Procedure for patients in need of metatarsus adductus and hallux valgus correction. Up to 80 subjects will be treated in this study at up to 13 clinical sites. Patients 14 years of age or older with symptomatic metatarsus adductus and hallux valgus will be eligible to participate based on the inclusion and exclusion criteria defined in the study protocol.

Eligibility Criteria

Inclusion Criteria: 1. Male and females ≥14 years old at the time of consent 2. Closed physeal plates at the time of consent 3. Intermetatarsal angle is ≥8.0˚; OR True IMA of \>10°, (IMA+MTA-15=True IMA) 4. Hallux valgus angle is ≥12.0˚ 5. Metatarsus adductus angle based on Sgarlatos method ≥15° 6. Willing and able to adhere to post-op care instructions 7. Capable of completing self-administered questionnaires 8. Acceptable surgical candidate, including use of general anesthesia 9. Female patients must be of non-childbearing potential or have a negative pregnancy test in accordance with hospital standards prior to the Index Procedure 10. Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits 11. Willing and able to provide written informed consent 12. Patient agrees to refrain from any reconstructive procedures on contralateral foot for minimum of 6 months post index procedure Exclusion Criteria: 1. Previous surgery for hallux valgus on operative side 2. Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe, lesser toes/digits, or posterior muscle lengthening) 3. Moderate-severe osteoarthritis of the foot or ankle outside of the 1st, 2nd or 3rd tarsometatarsal joints 4. Severe osteoarthritis of the 1st, 2nd or 3rd tarsometatarsal joints 5. Any deformity of the hindfoot or midfoot that represents a pathological condition that may affect the outcome of the tarsometatarsal realignment, or a condition that requires concomitant surgical correction 6. BMI \>40 kg/m² 7. Current nicotine user in any form including vaping, smoking, oral ingestion or use of nicotine patch 8. Current clinical diagnosis of diabetes or currently taking medication for treatment of diabetes 9. Current clinical diagnosis of peripheral neuropathy 10. Current clinical diagnosis of fibromyalgia 11. Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD) 12. Current uncontrolled hypothyroidism 13. Current clinical diagnosis of chronic dependent edema 14. Previously sensitized to titanium 15. Currently taking oral steroids or rheumatoid biologics 16. Currently taking immunosuppressant drugs 17. Insufficient quantity or quality of bone to permit stabilization, conditions that inhibit healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease 18. Active, suspected, or latent infection in the affected area 19. Use of synthetic or allogenic bone graft substitutes 20. Use of non-Treace products for Index Procedure 21. Additional bone procedure needed during the index procedure to complete correction \[first MTP fusion, calcaneal osteotomy, traditional medial eminence resection, additional metatarsal or tarsal bone osteotomy or fusion (other than Weil osteotomies)\]; 22. Scheduled to undergo a same-day bilateral procedure 23. Patient has previously been enrolled into this study for a contralateral procedure 24. Scheduled for any concomitant procedure that would alter patient's ability to weight-bear post-procedure 25. Patient is actively involved with a workman's compensation case or is currently involved in litigation 26. Patient is currently in, or has participated in, a clinical study in the last 30 days prior to signing informed consent or is considering participation in another research protocol during this study. Exceptions to this include survey clinical studies with no treatment or if subject is greater than 12 months post procedure in either the Treace ALIGN3D™ or Mini3D™ Study without ongoing protocol defined AE 27. Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up

Contact & Investigator

Frequently Asked Questions

Related Trials